Terns Pharmaceuticals Inc (TERN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
May 17, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals SG&A Expense (Quarterly): 6.859M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.859M |
| December 31, 2023 | 6.599M |
| September 30, 2023 | 18.35M |
| June 30, 2023 | 7.008M |
| March 31, 2023 | 7.101M |
| December 31, 2022 | 6.17M |
| September 30, 2022 | 5.131M |
| June 30, 2022 | 5.422M |
| March 31, 2022 | 5.689M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.416M |
| September 30, 2021 | 4.715M |
| June 30, 2021 | 4.857M |
| March 31, 2021 | 4.561M |
| December 31, 2020 | 0.998M |
| September 30, 2020 | 3.333M |
| June 30, 2020 | 2.486M |
| March 31, 2020 | 2.179M |
| December 31, 2019 | 2.388M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.998M
Minimum
Dec 2020
18.35M
Maximum
Sep 2023
5.515M
Average
5.274M
Median
SG&A Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 9.97M |
| Eli Lilly and Co | 1.836B |
| Pfizer Inc | 3.495B |
| Amgen Inc | 1.808B |
| Madrigal Pharmaceuticals Inc | 80.80M |